JMP Securities Initiates Coverage on AtriCure to Outperform

JMP Securities Initiates Coverage on AtriCure(NASDAQ:ATRC). The shares have been rated Outperform. The rating by JMP Securities was issued on Jun 30, 2016.

AtriCure (ATRC) made into the market gainers list on Tuesdays trading session with the shares advancing 0.28% or 0.04 points. Due to strong positive momentum, the stock ended at $14.48, which is also near the day’s high of $14.775. The stock began the session at $14.42 and the volume stood at 1,15,480 shares. The 52-week high of the shares is $28.15 and the 52 week low is $13.44. The company has a current market capitalization of $479 M and it has 3,30,94,148 shares in outstanding.

AtriCure(ATRC) last announced its earnings results on Apr 28, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $35.94M. Analysts had an estimated revenue of $35.78M. Earnings per share were $-0.31. Analysts had estimated an EPS of $-0.33.

Several Insider Transactions has been reported to the SEC. On Mar 9, 2016, Elizabeth D Krell (director) sold 10,000 shares at $16.91 per share price.Also, On Dec 7, 2015, Douglas J Seith (Chief Operating Officer) sold 5,000 shares at $21.55 per share price.On May 8, 2015, Karen P Robards (director) sold 2,650 shares at $22.18 per share price, according to the Form-4 filing with the securities and exchange commission.

AtriCure Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The Company’s Isolator Synergy System which includes its Isolator Synergy clamps generator and switchbox is used for the treatment of persistent and long-standing persistent Afib in patients who are undergoing open concomitant coronary artery bypass grafting and valve replacement or repair. The cryoICE cryosurgery product line offers a range of both single use and reusable cryoablation devices. The AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA). Its radiofrequency (RF) ablation products are indicated for the ablation of cardiac tissue. The Company sells enabling technologies including its Lumitip dissectors and Endoscopic Technologies Inc.’s (Estech) line of reusable cardiac surgery instruments.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

AtriCure - Is it time to Sell?

Top Brokerage Firms are advising their investors on AtriCure. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.